Mergers and Acquisitions (M&A) for Biocept, Inc. (BIOC)

Add BIOC to watchlist(s)

You Should Create a Watchlist In The First Place.

Price Over Time

Profile

Company Name

Biocept, Inc.

Symbol

BIOC

Currency

USD

Exchange

Nasdaq

Head Quarter

United States, San Diego

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Website

https://biocept.com

ISIN

US09072V6002

CIK

1044378

CUSIP

09072V402

UEI

-

LEI

-

Business Description

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians;

Biocept, Inc.

Mergers & Acquisitions Beta

M&A Deals · Breakdown

M&A Deals · History